罕见血友病因素市场 - 全球产业规模、份额、趋势、机会和预测，按治疗、类型、地区和竞争细分，2020-2030 年预测

2024 年全球罕见血友病因素市场价值为 3.2425 亿美元，预计到 2030 年将达到 4.7514 亿美元，预测期内复合年增长率为 6.58%。全球罕见血友病因素市场是广泛医疗保健产业中一个充满活力且至关重要的领域，专注于满足患有罕见血友病患者的独特需求。血友病是一种罕见的遗传性疾病，其特征是缺乏或缺乏特定的凝血因子，主要是因子 VIII（血友病 A）和因子 IX（血友病 B）。然而，还有更罕见的血友病，是由其他凝血因子缺乏引起的，包括因子 I、V、VII、X、XI 和 XIII。这些罕见的血友病变异在诊断、治疗和患者护理方面带来了独特的挑战。

罕见血友病因子市场涵盖一系列专门针对与这些罕见凝血因子疾病相关的特定缺陷的产品和疗法。这些治疗旨在取代缺失的凝血因子或增强患者现有凝血因子的功能。近年来，创新疗法的开发取得了重大进展，其中包括基因疗法，预计将为患有罕见血友病因素的患者提供长期缓解。

市场的成长受到多种因素的推动，包括由于诊断和认识的提高而导致的罕见血友病因素疾病的患病率不断增加、发展中国家医疗保健基础设施的扩大，以及旨在改善治疗方案的持续研发努力。此外，製药公司、研究机构和患者权益团体之间的合作与伙伴关係也加速了该领域的进步。

主要市场驱动因素

盛行率上升和诊断水准提高

主要市场挑战

治疗费用高昂

主要市场趋势

基因治疗的突破

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：全球罕见血友病因素市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依治疗方法（因子浓缩物、新鲜冷冻血浆、冷沉淀物、其他）
  • 依类型（因子 I、因子 II、因子 V、因子 VII、因子 X、因子 XI、因子 XIII）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按治疗
  • 按类型
  • 按地区

第 5 章：亚太地区罕见血友病因素市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按治疗
  • 按类型
  • 按国家
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 6 章：欧洲罕见血友病因素市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 7 章：北美罕见血友病因素市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲罕见血友病因素市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 9 章：中东和非洲罕见血友病因素市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 埃及

第 10 章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 治疗启动
• 合併与收购

第 12 章：全球罕见血友病因素市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Novo Nordisk A/S
• Biogen
• Bayer AG
• Pfizer, Inc.
• Shire Pharmaceuticals
• Baxalta (Baxter Healthcare)
• CSL Behring
• Bio Products Laboratory Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Alexion Pharmaceuticals, Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

Global Rare Hemophilia Factors Market was valued at USD 324.25 million in 2024 and is expected to reach USD 475.14 million by 2030 with a CAGR of 6.58% during the forecast period. The Global Rare Hemophilia Factors Market is a dynamic and vital sector within the broader healthcare industry, focused on addressing the unique needs of individuals suffering from rare forms of hemophilia. Hemophilia is a rare genetic disorder characterized by the absence or deficiency of specific blood clotting factors, primarily Factor VIII (hemophilia A) and Factor IX (hemophilia B). However, there are even rarer forms of hemophilia that result from deficiencies in other clotting factors, including Factors I, V, VII, X, XI, and XIII. These rare hemophilia variants present distinct challenges in terms of diagnosis, treatment, and patient care.

The market for rare hemophilia factors encompasses a range of products and therapies tailored to address the specific deficiencies associated with these rare clotting factor disorders. These treatments are designed to either replace the missing clotting factors or enhance the function of the patient's existing clotting factors. In recent years, there have been significant advancements in the development of innovative therapies, including gene therapy, which holds promise for long-term relief for individuals with rare hemophilia factors.

The market's growth is driven by several factors, including the increasing prevalence of rare hemophilia factor disorders due to improved diagnosis and awareness, the expansion of healthcare infrastructure in developing countries, and ongoing research and development efforts aimed at improving treatment options. Additionally, collaborations and partnerships between pharmaceutical companies, research institutions, and patient advocacy groups have accelerated progress in the field.

Key Market Drivers

Rising Prevalence and Improved Diagnosis

Rising prevalence and improved diagnosis are among the foremost factors propelling the growth of the Global Rare Hemophilia Factors Market. Historically, patients with rare hemophilia factor deficiencies often faced delayed or misdiagnoses due to the complexities and the rarity of these disorders. However, in recent years, there has been a significant shift in the healthcare landscape with enhanced awareness, better diagnostic tools, and more comprehensive genetic testing.

The increasing prevalence of rare hemophilia factor deficiencies can be attributed, in part, to improved diagnosis. As healthcare professionals become more knowledgeable about these fewer common forms of hemophilia, more patients are correctly identified and diagnosed. This growing awareness, often fostered by patient advocacy groups, has led to a surge in demand for specialized therapies and treatments tailored to these unique clotting factor disorders. This, in turn, fuels the market by creating a larger patient pool seeking appropriate care.

Advancements in diagnostic technologies, particularly genetic testing, have been pivotal in this context. These tests enable healthcare providers to pinpoint the exact clotting factor deficiency and its genetic basis, allowing for precise and early diagnoses. Such early diagnosis is crucial because it enables timely intervention and personalized treatment strategies, significantly improving patient outcomes. Patients who were once left undiagnosed or misdiagnosed can now receive tailored care, leading to a better quality of life.

Furthermore, as the prevalence of rare hemophilia factor disorders becomes more apparent, healthcare systems worldwide are recognizing the importance of addressing these conditions and allocating resources to support affected individuals. This commitment is fostering a more patient-centric approach in healthcare, driving the development of novel therapies and treatment options.

Key Market Challenges

High Treatment Costs

The Global Rare Hemophilia Factors Market has made significant strides in addressing the unique needs of individuals with rare clotting factor deficiencies. While advancements in therapies have offered new hope to these patients, a pervasive challenge looms large - the high cost of treatment. The exorbitant price of specialized therapies designed for rare hemophilia factors is a key obstacle in achieving equitable access and comprehensive care for affected individuals.

Rare hemophilia factor deficiencies encompass various disorders that result from the deficiency of clotting factors other than the commonly known Factors VIII (hemophilia A) and IX (hemophilia B). These conditions, which include deficiencies in Factors I, V, VII, X, XI, and XIII, present unique challenges in diagnosis and management. As a result, specialized treatments are required, which are often considerably more expensive than traditional clotting factor replacement therapies.

The high treatment costs can be a significant financial burden for both patients and healthcare systems. For patients, it can lead to personal financial strain, jeopardizing their access to the critical care they need. In many cases, individuals with rare hemophilia factor deficiencies find themselves grappling with out-of-pocket expenses that are simply unaffordable. This financial burden can result in treatment non-compliance, reduced quality of life, and overall health complications.

Key Market Trends

Gene Therapy Breakthroughs

Gene therapy breakthroughs have emerged as a powerful driving force in the Global Rare Hemophilia Factors Market. Rare hemophilia factor deficiencies, resulting from the absence or dysfunction of specific clotting factors, have long presented significant challenges in terms of treatment. However, recent breakthroughs in gene therapy are fundamentally transforming the landscape of care for individuals with these conditions, offering newfound hope, improved outcomes, and a promising shift away from lifelong clotting factor replacement therapy.

Gene therapy for rare hemophilia factors involves the introduction of a functional copy of the deficient clotting factor gene into the patient's cells, addressing the root genetic cause of the deficiency. This innovative approach has yielded remarkable results, offering potential cures rather than just symptom management. Clinical trials have demonstrated the safety and efficacy of gene therapy in treating rare hemophilia, showing that it can lead to sustained production of the deficient clotting factor, reducing or eliminating the need for regular infusions of clotting factor concentrates.

Key Market Players

• Novo Nordisk A/S
• Biogen
• Bayer AG
• Pfizer, Inc.
• Shire Pharmaceuticals
• Baxalta (Baxter Healthcare)
• CSL Behring
• Bio Products Laboratory Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Alexion Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Rare Hemophilia Factors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rare Hemophilia Factors Market, By Treatment:

• Factor Concentrates
• Fresh Frozen Plasma
• Cryoprecipitate
• Others

Rare Hemophilia Factors Market, By Type:

• Factor I
• Factor II
• Factor V
• Factor VII
• Factor X
• Factor XI
• Factor XIII

Rare Hemophilia Factors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rare Hemophilia Factors Market.

Available Customizations:

Global Rare Hemophilia Factors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Rare Hemophilia Factors Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate, Others)
  • 4.2.2. By Type (Factor I, Factor II, Factor V, Factor VII, Factor X, Factor XI, Factor XIII)
  • 4.2.3. By Region
  • 4.2.4. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Treatment
  • 4.3.2. By Type
  • 4.3.3. By Region

5. Asia Pacific Rare Hemophilia Factors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment
  • 5.2.2. By Type
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Rare Hemophilia Factors Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment
      • 5.3.1.2.2. By Type
  • 5.3.2. India Rare Hemophilia Factors Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment
      • 5.3.2.2.2. By Type
  • 5.3.3. Australia Rare Hemophilia Factors Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment
      • 5.3.3.2.2. By Type
  • 5.3.4. Japan Rare Hemophilia Factors Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment
      • 5.3.4.2.2. By Type
  • 5.3.5. South Korea Rare Hemophilia Factors Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment
      • 5.3.5.2.2. By Type

6. Europe Rare Hemophilia Factors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Type
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Rare Hemophilia Factors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Type
  • 6.3.2. Germany Rare Hemophilia Factors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Type
  • 6.3.3. Spain Rare Hemophilia Factors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Type
  • 6.3.4. Italy Rare Hemophilia Factors Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment
      • 6.3.4.2.2. By Type
  • 6.3.5. United Kingdom Rare Hemophilia Factors Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment
      • 6.3.5.2.2. By Type

7. North America Rare Hemophilia Factors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Type
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Rare Hemophilia Factors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Type
  • 7.3.2. Mexico Rare Hemophilia Factors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Type
  • 7.3.3. Canada Rare Hemophilia Factors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Type

8. South America Rare Hemophilia Factors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Type
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Rare Hemophilia Factors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Type
  • 8.3.2. Argentina Rare Hemophilia Factors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Type
  • 8.3.3. Colombia Rare Hemophilia Factors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Type

9. Middle East and Africa Rare Hemophilia Factors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Type
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Rare Hemophilia Factors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Type
  • 9.3.2. Saudi Arabia Rare Hemophilia Factors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Type
  • 9.3.3. UAE Rare Hemophilia Factors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Type
  • 9.3.4. Egypt Rare Hemophilia Factors Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Treatment
      • 9.3.4.2.2. By Type

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Treatment Launches
• 11.3. Mergers & Acquisitions

12. Global Rare Hemophilia Factors Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Novo Nordisk A/S
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Biogen
• 14.3. Bayer AG
• 14.4. Pfizer, Inc.
• 14.5. Shire Pharmaceuticals
• 14.6. Baxalta (Baxter Healthcare)
• 14.7. CSL Behring
• 14.8. Bio Products Laboratory Ltd.
• 14.9. Takeda Pharmaceutical Co. Ltd.
• 14.10. Alexion Pharmaceuticals, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer